Palvella Therapeutics (PVLA) Preferred Stock Liabilities (2022 - 2023)
Palvella Therapeutics' (PVLA) quarterly Preferred Stock Liabilities came in at $70.6 million in Q4 2023, little changed year-on-year from $70.6 million in Q4 2022, and little changed on a QoQ basis from $70.6 million in Q4 2022.
Palvella Therapeutics (PVLA) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
Palvella Therapeutics (PVLA) has 2 years of Preferred Stock Liabilities data on file, last reported at $70.6 million in Q4 2023.
- On a quarterly basis, Preferred Stock Liabilities changed 0.0% year-over-year to $70.6 million in Q4 2023; TTM through Dec 2023 was $70.6 million, a 0.0% change from a year earlier, with the FY2023 full-year figure at $70.6 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities for Q4 2023 stood at $70.6 million, roughly flat from $70.6 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for PVLA reached as high as $70.6 million in Q4 2022 and fell as low as $70.6 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Palvella Therapeutics | 1.84 Bn | 1.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 70.60 Mn |
| Dec 31, 2022 | 70.60 Mn |